CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
Treatment A +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT07214922
NCT07214922Phase 1Completed
CompareCT.gov

A Phase I, Open-Label Study of the Relative Bioavailability of Evobrutinib Tablet Manufacturing Batches in Healthy Participants

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany·interventional·Posted Oct 9, 2025·Updated Dec 23, 2025

In Brief

A Phase 1 clinical trial evaluating Treatment A, Treatment B, and 2 other interventions for Healthy. Completed, enrolled 28 participants across 1 site.

Detailed Summary

The main purpose of the study is to compare the Pharmacokinetics (PK), safety and tolerability of different manufacturing batches of M2951 tablet formulation relative to a reference batch under fasted conditions in healthy participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesGermany
Collaborators--

Timeline

Phase 1CompletedFinished
2023202420252026
First PostedOct 9, 2025
Enrollment StartJan 18, 2023
Primary CompletionFeb 24, 2023
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 9 months ago

Interventions

Treatment Adrug

Participants will receive single dose of Treatment A in treatment period 1, 2, 3 or 4 under fasted conditions.

Treatment Bdrug

Participants will receive single dose of Treatment B in treatment period 1, 2, 3 or 4 under fasted conditions.

Treatment Cdrug

Participants will receive single dose of Treatment C in treatment period 1, 2, 3 or 4 under fasted conditions.

Treatment Ddrug

Participants will receive single dose of Treatment D in treatment period 1, 2, 3 or 4 under fasted conditions.